Union Health Minister Releases 10th Edition of Indian Pharmacopoeia

Union Minister for Health and Family Welfare and Chemicals and Fertilizers, J. P. Nadda, on 2 January 2026 released the 10th edition of the Indian Pharmacopoeia (IP 2026), marking a significant step in strengthening India’s pharmaceutical quality and regulatory framework.

About the Indian Pharmacopoeia
The Indian Pharmacopoeia is the country’s official book of drug standards, playing a central role in ensuring the safety, quality and efficacy of medicines manufactured and sold in India. It is published by the Indian Pharmacopoeia Commission on behalf of the Ministry of Health and Family Welfare under the Drugs and Cosmetics Act, 1940, and its standards are legally enforceable.

Key Additions in IP 2026
IP 2026 incorporates 121 new monographs, taking the total to 3,340 monographs. The expanded coverage includes:

• Anti-tubercular medicines
• Anti-diabetic drugs
• Anti-cancer medicines
• Iron supplements used under national health programmes

First-Time Inclusion of Blood Component Standards
A major highlight of IP 2026 is the first-ever inclusion of 20 blood component monographs related to transfusion medicine, aligned with the Drugs and Cosmetics (Second Amendment) Rules, 2020.

Global Recognition and Health Diplomacy
The Union Minister noted that the Indian Pharmacopoeia has gained international recognition and is now accepted in 19 countries of the Global South, reflecting India’s growing role in global health diplomacy and pharmaceutical regulation.

Progress in Pharmacovigilance
Highlighting India’s achievements in drug safety monitoring, Nadda said India has risen from 123rd position (2009–2014) to 8th globally in 2025 in contributions to the WHO’s pharmacovigilance database, under the Pharmacovigilance Programme of India (PvPI).

Harmonisation with Global Standards
India is actively collaborating with international pharmacopoeias through the Pharmacopoeial Discussion Group to harmonise standards in line with International Council for Harmonisation (ICH) norms, further strengthening the global acceptance of Indian drug standards.